Patent classifications
A61K9/70
METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS
The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.
EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE
The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.
DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING
The invention is describing an intrauterine delivery system comprising non-steroidal anti-inflammatory (NSAID) and a progestogenic compound, containing anti-inflammatory active compound in the frame material and that the progestogenic compound is contained in a silicon based reservoir attached to the frame, wherein the frame consist of a thermoplastic material. A further object of the invention is to fabricate drug-containing T-intrauterine systems (I US) with the drug incorporated within the entire backbone of the medical device by using 3D printing technique, based on fused deposition modelling (FDM™). Indomethacin was used to prepare drug-loaded poly-caprolactone (PCL)-based filaments with different drug contents 5-40 wt %, namely 5%, 15% and 30% wt %: of Indomethacin.
DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING
The invention is describing an intrauterine delivery system comprising non-steroidal anti-inflammatory (NSAID) and a progestogenic compound, containing anti-inflammatory active compound in the frame material and that the progestogenic compound is contained in a silicon based reservoir attached to the frame, wherein the frame consist of a thermoplastic material. A further object of the invention is to fabricate drug-containing T-intrauterine systems (I US) with the drug incorporated within the entire backbone of the medical device by using 3D printing technique, based on fused deposition modelling (FDM™). Indomethacin was used to prepare drug-loaded poly-caprolactone (PCL)-based filaments with different drug contents 5-40 wt %, namely 5%, 15% and 30% wt %: of Indomethacin.
Preserved Silk Protein Fragment Compositions and Articles Manufactured Therefrom
In some embodiments, a composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. In some embodiments, a composition is disclosed that includes silk fibroin-based protein fragments and is suitable for use in consumer applications. In some embodiments, a preserved composition is disclosed that includes silk fibroin-based protein fragments. In some embodiments, a method of preserving a solution using silk fibroin-based protein fragments is disclosed.
COMPOSITION COMPRISING CHITOSAN FOR USE IN THE PREVENTION AND/OR IN THE TREATMENT OF INCONTINENCE AND/OR IMPOTENCE IN A SUBJECT UNDERGOING PROSTATECTOMY
Composition comprising chitosan for use in the prevention and/or treatment of incontinence and/or impotence in a subject undergoing prostatectomy.
TRANSDERMAL DELIVERY SYSTEM CONTAINING GALANTAMINE OR SALTS THEREOF
Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Alzheimer's disease. Kits including the transdermal delivery system and methods of making such delivery system are also provided.
Antimicrobial Articles
Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to form chlorhexidine-containing polymer of the antimicrobial article, wherein processing temperature during the method is less than about 80° C.
METHODS AND SYSTEMS FOR DEPOSITING ACTIVE INGREDIENTS ON SUBSTRATES
Systems and methods for delivering active ingredients, such as pharmaceutically active ingredients, to substrates are described herein. The active ingredients are delivered as fluids to a fluiddispensing device for the creation of one or more drops for deposition onto substrates such as for the creation of microdoses. The invention further includes microdoses made by such processes.
LASOFOXIFENE TREATMENT OF BREAST CANCER
The disclosure provides methods for treating estrogen receptor positive (ER.sup.+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER.sup.+ cancers.